Ultragenyx has finalized the rolling submission of its Biologics License Application to the FDA for DTX401, an AAV8 gene therapy targeting Glycogen Storage Disease Type Ia. The filing incorporates data from 52 treated patients with up to six years of follow-up, including Phase 3 GlucoGene results showing significant reductions in both quantity and frequency of daily cornstarch intake, maintenance of euglycemia, improved fasting tolerance and meaningful gains on the Patient Global Impression of Change scale. The submission package now includes non-clinical, clinical and CMC modules, with DTX401 holding Fast Track, RMAT, orphan drug and PRIME designations in key jurisdictions.

Ultragenyx shares surged by more than 15% on above-average volume following the announcement of BLA submission completion, reflecting investor enthusiasm for the potential approval of a first-in-class therapy that addresses the underlying cause of GSDIa. Trading volume exceeded three times the 30-day average, underscoring heightened market interest in the company’s regulatory trajectory and its broader rare-disease pipeline.

Earlier in the quarter, Ultragenyx and partner Mereo BioPharma disclosed that two Phase 3 studies of setrusumab in osteogenesis imperfecta failed to meet primary endpoints but achieved statistically significant secondary improvements in bone mineral density. In response, several firms lowered their earnings estimates and price targets—one major brokerage reduced its target by over 30% yet maintained an overweight view, citing a favorable risk-reward profile and anticipating FDA feedback. Management has emphasized the need to evaluate secondary data and explore additional development pathways before making further strategic decisions.